NextCure (NXTC) Non-Current Assets (2018 - 2026)
NextCure (NXTC) posted quarterly Non-Current Assets of $6.2 million for Q1 2026, down 24.32% year-over-year from $8.2 million in Q1 2025, and down 3.11% quarter-over-quarter from $6.4 million in Q4 2025.
NextCure (NXTC) Non-Current Assets (2018 - 2026) Analysis & Trends
NextCure's Non-Current Assets history runs 9 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 24.32% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $27.3 million (down 33.5% YoY), while the FY2025 annual figure was $6.4 million, down 28.91% from the prior year.
- Non-Current Assets for Q1 2026 stood at $6.2 million, down from $6.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $20.2 million in Q4 2022, with the low at $6.2 million in Q1 2026.
- The 5-year median for Non-Current Assets is $12.6 million (2024), against an average of $12.5 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 38.5% in 2022, then slumped 40.88% in 2024.
- NextCure's Non-Current Assets stood at $20.2 million in 2022, then retreated by 24.11% to $15.3 million in 2023, then plunged by 40.88% to $9.1 million in 2024, then dropped by 28.91% to $6.4 million in 2025, then decreased by 3.11% to $6.2 million in 2026.
- Business Quant data shows NXTC's Non-Current Assets at $6.2 million in Q1 2026, $6.4 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 365,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 365,000.00 |
| Mar 31, 2026 | 6.24 Mn |
| Dec 31, 2025 | 6.44 Mn |
| Sep 30, 2025 | 6.97 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Mar 31, 2025 | 8.24 Mn |
| Dec 31, 2024 | 9.05 Mn |
| Sep 30, 2024 | 11.65 Mn |
| Jun 30, 2024 | 12.13 Mn |
| Mar 31, 2024 | 12.61 Mn |
| Dec 31, 2023 | 15.31 Mn |
| Sep 30, 2023 | 17.26 Mn |
| Jun 30, 2023 | 18.08 Mn |
| Mar 31, 2023 | 18.87 Mn |
| Dec 31, 2022 | 20.18 Mn |
| Sep 30, 2022 | 14.59 Mn |
| Jun 30, 2022 | 13.42 Mn |
| Mar 31, 2022 | 13.81 Mn |
| Dec 31, 2021 | 14.57 Mn |
| Sep 30, 2021 | 14.79 Mn |